|Manufacturer:||Kumudini Pharma Ltd.|
|Last Updated:||2020-11-22 18:15:00|
Antidiar Capsule contains Racecadotril. Antidiar uses:
Antidiar Capsule is indicated for the symptomatic treatment of acute diarrhea.
Antidiar Capsule is a pure intestinal antisecretory active substance. It decreases the intestinal hypersecretion of water and electrolytes induced by cholera toxin or inflammation and does not have effects on basal secretory activity.
Following oral administration, Antidiar Capsule is rapidly absorbed and then hydrolysed to thiorphan, which is an inhibitor of enkephalinase, a cell membrane peptidase located in various tissues, notably the epithelium of the small intestine. This enzyme contributes both to the hydrolysis of exogenous peptides and to the breakdown of endogenous peptides such as enkephalins. Antidiar Capsule protects enkephalins from enzymatic degradation thereby prolonging their action at enkephalinergic synapses in the small intestine and reducing hypersecretion. Antidiar Capsule exerts rapid antidiarrhoeal action, without modifying the duration of intestinal transit.
Antidiar Capsule contains Racecadotril 100 mg. Antidiar doses:
Adults: One capsule initially, regardless of the time of day. Then one capsule three times daily preferably before the main meals.
Children (from 3 months of age): Antidiar Capsule granules should be administered together with oral rehydration. The recommended dose is determined according to body weight: 1.5 mg/kg per administration, three times daily.
Headache, erythema multiforme, urticaria, angioedema may be seen.
Antidiar Capsule increases the availability of endogenous opioids (enkephalins) by inhibiting the membrane-bound enkephalinase. The enkephalins in turn mediate their effect through δ receptor ( delta opioid receptor) activation that induces a selective increase in Cl absorption by inhibiting adenylate cyclase.
Onset: 30 min (plasma enkephalinase inhibition).
The administration of Antidiar Capsule does not modify the usual rehydration regimens. The presence of bloody stools and fever may indicate the presence of invasive bacteria as a reason for diarrhea or the presence of other severe disease. Antidiar Capsule has not been tested in antibiotic-associated diarrhea and should therefore not be administered under these conditions. Caution should be taken in patients with renal or liver impairment.
No drug interactions found. Joint treatment with Antidiar Capsule and Loperamide or Nifuroxazide does not modify the kinetics of Antidiar Capsule.
Due to a lack of clinical data, Antidiar Capsule should not be administered to pregnant or breastfeeding women.
Hypersensitivity to Antidiar Capsule, or to any of the excipients.
No cases of overdose have been reported. In adults, single doses above 2 g which is equivalent to 20 times the therapeutic dose, have been administered, and no harmful effects have been described.
Antidiar Capsule price in Bangladesh 0.00